PLUS THERAPEUTICS, INC.PSTV
| Dec 31,
2011 | Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 |
|---|
| Net loss | -32,451,000 | -32,279,000 | -26,177,000 | -37,368,000 | -18,744,000 | -22 | -23 | -13 | -11 | -8 | -13 | -20 |
|---|
| Depreciation and amortization | 855,000 | 933,000 | 2 | 779,000 | 1 | 1 | 2 | 2 | 1 | 0 | 0 | 1 |
|---|
| Amortization of Debt Issuance Costs and Discounts | 711,000 | 930,000 | 893,000 | 1 | 979,000 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
|---|
| Research and Development in Process | - | - | - | - | - | - | - | - | - | 1 | 0 | - |
|---|
| Fair Value Adjustment of Warrants | - | - | - | -369,000 | -7,668,000 | - | - | -2 | -3 | -2 | -0 | -0 |
|---|
| Loss on disposal of property and equipment | - | - | -257,000 | 42,000 | 3,000 | - | - | - | - | - | -0 | - |
|---|
| Share-based compensation expense | 3 | 4 | 4 | 3 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
|---|
| Amortization of operating lease right-of-use assets | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Other current assets | - | 324,000 | 24,000 | -510,000 | 637,000 | -1 | 1 | -0 | 0 | -0 | 0 | 2 |
|---|
| Accounts payable and accrued expenses | -1,436,000 | 1 | -409,000 | -1,147,000 | 1 | -1 | -2 | -2 | -0 | -1 | 2 | 6 |
|---|
| Change in operating lease liabilities | - | - | - | - | - | - | - | - | - | - | - | -0 |
|---|
| Other long-term liabilities | - | - | - | - | - | - | - | - | -0 | - | - | 2 |
|---|
| Net cash used in operating activities | -35,323,000 | -32,193,000 | -34,563,000 | - | - | - | - | -12 | -6 | -8 | -10 | -13 |
|---|
| Purchases of property and equipment and intangible assets | - | - | - | - | - | - | - | - | - | 0 | 0 | 1 |
|---|
| In process research and development acquired | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Proceeds from sale of property and equipment | - | - | - | - | - | - | - | - | - | - | 0 | - |
|---|
| Net cash used in investing activities | -560,000 | -1,204,000 | 4 | -1,343,000 | - | - | - | -0 | 6 | -0 | -0 | -1 |
|---|
| Principal payments of long-term obligations | 5 | 3 | 22 | 2 | 25 | - | 5 | - | 4 | 5 | 0 | 2 |
|---|
| Payment of finance lease liability | - | - | - | - | - | - | - | - | 0 | 0 | 0 | - |
|---|
| Proceeds From Warrant Exercises1 | - | - | - | - | - | - | - | - | 0 | 1 | 2 | - |
|---|
| Proceeds from sale of common stock | 13 | 25 | 18 | 19 | 29 | 21 | 24 | - | 16 | 4 | 19 | 15 |
|---|
| Net cash provided by financing activities | 20 | 22 | 21 | - | - | - | - | 7 | 13 | -0 | 20 | 13 |
|---|
| Net increase (decrease) in cash and cash equivalents | - | - | - | - | - | - | - | -5 | 12 | -9 | 10 | -0 |
|---|
| Interest | - | - | - | - | - | - | - | 1 | 1 | 1 | 0 | 0 |
|---|
| Unpaid offering cost | - | - | - | - | - | - | - | - | - | 0 | 0 | - |
|---|
| Payments of Stock Issuance Costs | 194,000 | 1 | 184,000 | 425,000 | 2 | 2 | 2 | - | - | 0 | - | - |
|---|
| Common stock issued in payment for in process research and development | - | - | - | - | - | - | - | - | - | 0 | - | - |
|---|
| Reclassification of warrants liability to equity | - | - | - | - | - | - | - | - | 1 | 5 | - | - |
|---|